目的

探讨放射性¹²⁵I 粒子植入治疗口腔颌面部腺源性恶性肿瘤的疗效和并发症。

方法

选择15 例口腔颌面部腺源性恶性肿瘤患者，在治疗计划系统（TPS）引导下植入放射性¹²⁵I 粒子，粒子活度0.6 ～0.7 mCi（2.22 ～2.59 MBq），周边匹配剂量90 ～120 Gy。 术后复查并随访，观察患者的疗效和副反应。

结果

15 例患者均顺利完成放射性¹²⁵I 粒子植入，平均每例患者植入36.53 颗粒子。 手术后1 ～6 个月复查计算机体层摄影术，未出现粒子移位，局部控制良好，随访6 ～27 个月，治疗有效率为86.7%，未发现严重放疗副反应。

结论

TPS 引导下放射性¹²⁵I 粒子植入组织间近距离治疗口腔颌面部腺源性恶性肿瘤，安全可靠、创伤小，对控制复发及颈部淋巴转移近期效果显著。

Objective

To investigate the clinical effect and complications of the treatment with radioactive ¹²⁵I implantation for gland-derived oral maxillofacial malignancies.

Methods

Fifteen patients with gland-derived oral maxillofacial malignancies was included in this study， the radioactive ¹²⁵I particle was implanted with the guiding of TPS （treatment planning system）， particle activity was 0.6-0.7 mCi（2.22 - 2.59 MBq）， and the matched peripheral dose was 90 - 120 Gy. After operation， evaluate the effect and adverse reactions by follow-up.

Results

All of the patients were completed the implantation of radioactive ¹²⁵I particle， the average number of ¹²⁵I particle was 36.53 for each patient. After Surgery about 1-6 months， the CT results showed no shifting of the particle， local control was well， and the effective rate was 86.7% about 6 - 27 months later without serious radiation side effects.

Conclusion

The implantation of radioactive ¹²⁵I particle by the guide with TPS was safe， less invasive for glandderived oral maxillofacial malignancies， and has obvious effect in the controlling of relapse and cervical lymph node metastasis.